CoChat
Sign Up
Cited by 651Estrogen and related hormone effectsBreast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Mechanisms of tamoxifen resistance

Open access
Ring, Alistair, Dowsett, Mitch·2004·Endocrine-Related Cancer
DOI 10.1677/erc.1.00776
Open this paper in CoChat — free accountOpen PDF

Abstract

The anti-oestrogen tamoxifen is the most commonly used treatment for patients with oestrogen-receptor (ER)-positive breast cancer. Although many patients benefit from tamoxifen in the adjuvant and metastatic settings, resistance is an important clinical problem. The target of tamoxifen in vivo is the ER. Over the last decade many advances have been made in our understanding of the biology of the ER which may help to explain how resistance to tamoxifen develops. Such mechanisms may include changes in the expression of ERα or ERβ, alterations in co-regulatory proteins, and the influences of cellular kinase signal transduction pathways. The experimental and clinical evidence supporting these mechanisms of tamoxifen resistance are discussed in this review.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1677/erc.1.00776

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 119 · Cited by 651

Research works printed but not linked: 36

  1. Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D & Norton L 2000 HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node- positive breast cancer. Journal of Clinical Oncology 18 3471-3479.
  2. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S & Nakshatri H 2001 Phosphatidylinositol 3-kinase/ AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. Journal of Biological Chemistry 276 9817-9824 .
  3. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR & De Placido S 1996 c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. Journal of Clinical Oncology 14 2702-2708.
  4. Chung YL, Sheu ML, Yang SC, Lin CH & Yen SH 2002 Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. International Journal of Cancer 97 306-312.
  5. Clarke R, Currier S, Kaplan O, Lovelace E, Boulay V, Gottesman MM & Dickson RB 1992 Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. Journal of the National Cancer Institute 84 1506-1512.
  6. Clarke R, Skaar TC, Bouker KB, Davis N, Lee YR, Welch JN & Leonessa F 2001 Molecular and pharmacological aspects of antiestrogen resistance. Journal of Steroid Biochemistry and Molecular Biology 76 71-84.
  7. Cui Y, Hopp T & Fuqua SA 2002 A naturally occurring point mutation alters ERa crosstalk with regulatory signaling pathways. San Antonio Breast Cancer Symposium 76 Abstract 168.
  8. De Nardo D, Kim H, Thorn C, Wu K, Lee AV & Brown PH 2003 Estrogen's ability to stimulate breast cancer growth does not require ER DNA binding. San Antonio Breast Cancer Symposium 82 Abstract 1002.
  9. Dowsett M, Houghton J, Baum M, Salter J, A'Hern R, Iden C & Farndon J 1999 ER, PgR, c-ERBB2 and EGFR in patients randomised to adjuvant tamoxifen: combinations of biomarkers as discriminants of treatment benefit. San Antonio Breast Cancer Symposium 57 Abstract 222.
  10. Dowsett M & Haynes BP 2003 Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. Journal of Steroid Biochemistry and Molecular Biology 86 255-263.
  11. Dowsett M, Gutierrez C, Moshin S, Schiff R, Detre S, Johnston SR & Osborne CK 2003 Molecular changes in tamoxifen- relapsed breast cancer: Realtionship between ER, HER2 and P38-MAP-kinase, Proceedings of the American Society of Clinical Oncology, 39th Annual Meeting, Chicago, IL, USA. 22 Abstract 7.
  12. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E & Borgs M 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. Journal of Clinical Oncology 19 3808-3816.
  13. Gee JM, Robertson JF, Ellis IO & Nicholson RI 2001 Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. International Journal of Cancer 95 247-254.
  14. Gronemeyer H 1991 Transcription activation by estrogen and progesterone receptors. Annual Review of Genetics 25 89-123.
  15. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A & Morris C 2002 Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Journal of Clinical Oncology 20 3396-3403.
  16. Jaiyesimi IA, Buzdar AU, Decker DA & Hortobagyi GN 1995 Use of tamoxifen for breast cancer: twenty-eight years later. Journal of Clinical Oncology 13 513-529.
  17. Jarvinen TA, Pelto-Huikko M, Holli K & Isola J 2000 Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. American Journal of Pathology 156 29-35.
  18. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R & Grohe C 2000 Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. Journal of Biological Chemistry 275 18447-18453.
  19. Knoop AS, Bentzen SM, Nielsen MM, Rasmussen BB & Rose C 2001 Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. Journal of Clinical Oncology 19 3376-3384.
  20. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM & Webb P 2000 Estrogen receptor pathways to AP-1. Journal of Steroid Biochemistry and Molecular Biology 74 311-317.
  21. List HJ, Lauritsen KJ, Reiter R, Powers C, Wellstein A & Riegel AT 2001 Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. Journal of Biological Chemistry 276 23763-23768.
  22. Martens J, Nimmrich I, Koenig T, Look M, Harbeck N & Model F 2003 Epigenetic signature predicts failure of endocrine therapy in patients with recurrent breast cancer. San Antonio Breast Cancer Symposium Abstract 313.
  23. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Bottero D, Varricchio L, Nanayakkara M, Rotondi A & Auricchio F 2002 Sex steroid hormones act as growth factors. Journal of Steroid Biochemistry and Molecular Biology 83 31-35.
  24. Mosselman S, Polman J & Dijkema R 1996 ERb: identification and characterization of a novel human estrogen receptor. FEBS Letters 392 49-53.
  25. Omoto Y, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Kobayashi S & Iwase H 2001 Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Letters 163 207-212.
  26. Osborne CK, Coronado E, Allred DC, Wiebe V & DeGregorio M 1991 Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. Journal of the National Cancer Institute 83 1477-1482.
  27. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R & Buzdar A 2002 Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. Journal of Clinical Oncology 20 3386-3395.
  28. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM & Schiff R 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Journal of the National Cancer Institute 95 353-361.
  29. Razandi M, Pedram A, Park ST & Levin ER 2003 Proximal events in signaling by plasma membrane estrogen receptors. Journal of Biological Chemistry 278 2701-2712.
  30. Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, Dupont WD & Parl FF 1995 Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. Journal of the National Cancer Institute 87 446-451.
  31. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M & Hilsenbeck SG 2000 Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumour in vivo. Journal of National Cancer Institute 29 1926-1934.
  32. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer J-U, Ashley SE, Francis S, Boeddinghams I & Walsh G 2004 Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen or both in combination: the IMPACT multicentre double-blind randomised trial. Journal of Clinical Oncology (In Press).
  33. Stal O, Borg A, Ferno M, Kallstrom AC, Malmstrom P & Nordenskjold B 2000 ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Annals of Oncology 11 1545-1550.
  34. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z & Flockhart DA 2003 Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Journal of the National Cancer Institute 95 1758-1764.
  35. Vo N & Goodman RH 2001 CREB-binding protein and p300 in transcriptional regulation. Journal of Biological Chemistry 276 13505-13508.
  36. Zhang CC & Shapiro DJ 2000 Activation of the p38 mitogen- activated protein kinase pathway by estrogen or by 4- hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis. Journal of Biological Chemistry 75 479-486.

Authors
Ring, A., & Dowsett, M.
Affiliations
  • Royal Marsden Hospital (GB)
  • Institute of Cancer Research (GB)
ORCID
Venue
Endocrine-Related Cancer
Publisher
Bioscientifica
Published
2004-12-01
Volume
11
Issue
4
Pages
643-658
ISSN
  • 1351-0088 (ISSN-L)
  • 1479-6821
DOI
10.1677/erc.1.00776
OpenAlex
W2128605357
Cited by
651
References
119
Citations by year
2026: 10 · 2025: 14 · 2024: 16 · 2023: 33 · 2022: 25 · 2021: 40 · 2020: 41 · 2019: 22 · 2018: 37 · 2017: 33 · 2016: 48 · 2015: 37 · 2014: 45 · 2013: 42 · 2012: 39
FWCI
2.24
Type
journal article
Language
en
Open access
Locations
  • Endocrine Related Cancer (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Advanced Breast Cancer Therapies
Keywords
tamoxifen resistance, oestrogen receptor, estrogen receptor-positive breast cancer, estrogen receptor alpha, estrogen receptor beta, antiestrogen therapy
MeSH terms
Breast Neoplasms, Estrogen Antagonists, Female, Humans, Receptors, Estrogen, Tamoxifen, Transcription, Genetic, Signal Transduction, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review